IDEAYA Biosciences, Inc. (IDYA) analyst actions
Rating and price-target actions on IDYA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IDYA overview →
2 measured IDYA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers | Press release | -0.88% | +1.13% | |
| IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers | Press release | +0.80% | +2.68% |
Keep exploring
More IDYA: earnings → · SEC filings → · IDYA overview →